Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction

Werewolf Therapeutics (HOWL) and Ambros secured $150M in private funding, extending cash runway to 2029. The funds will support clinical trials and potential FDA filings. The merger, pending approval, is a key catalyst but carries risks. Analysts rate HOWL stock as 'Moderate Buy'.

Werewolf Therapeutics (HOWL) will merge with Ambros Therapeutics in an all-stock deal, with a $150M private placement. The combined company, Ambros Therapeutics, will trade as AMBX and focus on CRPS-1 treatments. The deal is expected to close by Q1 2027, pending approvals.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics announced an all-stock merger, creating a Nasdaq-listed biotech firm focused on neridronate for CRPS-1. The combined company, trading as AMBX, secured $150M in financing. Neridronate has FDA designations and is in Phase 3 trials, with results expected in 2028. The merger values Ambros at $500M and Werewolf at $47.5M, with a planned Q1 2027 close. HOWL shares surged 1431.19% in pre-market trading.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal, with the combined company focusing on Ambros's neridronate program. The deal includes a $150M private placement. Post-merger, Ambros will operate as AMBX on Nasdaq, led by its current team. Werewolf shares rose 125% pre-market to $0.95.

Werewolf Therapeutics (HOWL) stock surged 114.1% after announcing an all-stock merger with Ambros Therapeutics, valued at $500M pre-financing. The combined entity will focus on Ambros's lead drug, neridronate, for Complex Regional Pain Syndrome. The deal includes a $150M private placement and is expected to close by Q1 2027. Werewolf also recently sold its technology platforms to Merck KGaA for up to $33M.

Werewolf Therapeutics (NASDAQ: HOWL) shares rose 120% premarket after announcing a merger with Ambros Therapeutics and a $150M private placement. The combined company, trading as AMBX, will focus on neridronate for CRPS-1. The merger is expected to close in Q1 2027, with Ambros shareholders owning 71.7% of the new entity.